Human embryonic stem cell proliferation and differentiation as parameters to evaluate developmental toxicity

Journal of Cellular Physiology

Volumn 226, Issue 6, 2011, Pages 1583-1595

  Pal, Rajarshi ^a,b   Mamidi, Murali Krishna ^b   Kumar Das, Anjan ^b   Bhonde, Ramesh ^b  

^a Manipal Academy of Higher Education   (India)

^b Stempeutics Research Malaysia Sdn Bhd   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; CAFFEINE; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRADIOL; GREEN FLUORESCENT PROTEIN; HEPATOCYTE NUCLEAR FACTOR 3BETA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HYDROXYUREA; NESTIN; NUCLEAR RECEPTOR RELATED FACTOR 1; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PENICILLIN G; PROGESTERONE; REX PROTEIN; SYNAPTOPHYSIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX1; TRANSCRIPTION FACTOR SOX17; TRANSCRIPTION FACTOR SOX2;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CYTOTOXICITY; DNA CONTENT; DOWN REGULATION; DRUG EXPOSURE; EMBRYOID BODY; EMBRYONIC STEM CELL; ENDODERM; FLOW CYTOMETRY; GERM LAYER; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MESODERM; NERVE CELL DIFFERENTIATION; NEUROECTODERM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BIOLOGICAL MARKERS; CAFFEINE; CELL ADHESION; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CELL PROLIFERATION; CELL SHAPE; DOWN-REGULATION; EMBRYOID BODIES; EMBRYONIC STEM CELLS; HORMONES; HUMANS; HYDROXYUREA; MICE; NEURONS; ORGAN SPECIFICITY; PENICILLIN G; PLURIPOTENT STEM CELLS; QUALITY CONTROL; TOXICITY TESTS;

EID: 79952718925     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22484     Document Type: Article

References (51)

1. Adler S, Pellizzer C, Hareng L, Hartung T, Bremer S. 2002. First steps in establishing a developmental toxicity test method based on human embryonic stem cells. Toxicol In Vitro 22: 200-211.
2. Albrecht ED, Pepe GJ. 2010. Estrogen regulation of placental angiogenesis and fetal ovarian development during primate pregnancy. Int J Dev Biol 54: 397-408.
3. Anon. 1987. Teratology society position paper: Recommendations for vitamin A use during pregnancy. Teratology 2: 269-275.
4. Anon. 2001. OECD Guideline for Testing of Chemicals, Draft Guideline No 421: Reproduction/Developmental Toxicity Screening Test. Paris: Organisation for Economic Co-Operation and Development.
5. Bremer S, Worth AP, Paparella M, Bigot K, Kolossov E, Fleischmann BK, et al. 2001. Establishment of an in vitro reporter assay for the development of cardiac toxicity. Toxicol In Vitro 15: 215-223.
6. Busen R, Visan A, Genschow E, Slawik B, Spielmann H, Seiler A. 2004. Trends in improving the embryonic stem cell test (EST): An overview. ALTEX 21: 15-22.
7. Chow KM, Hui AC, Szeto CC. 2005. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 24: 649-653.
8. Classen W, Krinke GJ, Weber E. 2001. Developmental neurotoxicity study in rats: A positive control study with dimethylmercury and hydroxyurea. Neurotoxicology 22: 530.
9. Davila JC, Cezar GG, Thiede M, Strom S, Miki T, Trosko J. 2004. Use and application of stem cells in toxicology. Toxicol Sci 79: 214-223.
10. DeLorey TM, Olsen RW. 1992. Gamma-aminobutyric acid A receptor structure and function. J Biol Chem 267: 16747-16750.
11. Eckardt K, Stahlmann R. 2010. Use of two validated in vitro tests to assess the embryotoxic potential of mycophenolic acid. Arch Toxicol 84: 37-43.
12. Emmanouil EN, Frangou H, Nikoloussis E, Manthou ME, Lycartsis C, Massouridou S, et al. 2005. Histological and functional disorganisation in pregnant mice liver treated with all trans-retinonic acid and hydroxyurea. Reprod Toxicol 20: 460-461.
13. Fabro S. 1973. Passage of drugs and other chemicals into the uterine fluids and pre-implantation blastocyst. In: Boreus L, editor. Fetal pharmacology. New York, USA: Plenum Press. pp 443-459.
14. Genschow E, Scholz G, Brown N, Piersma A, Brady M, Clemann N, Huuskonen H, Paillard F, Bremer S, Becker K, Spielmann H. 2000. Development of prediction models for three in vitro embryotoxicity tests in an ECVAM validation study. In Vitr Mol Toxicol 13: 51-66.
15. Genschow E, Spielmann H, Scholz G, Pohl I, Seiler A, Clemann N, Bremer S, Becker K. 2004. Validation of the embryonic stem cell test (EST) in the international ECVAM validation study of three in vitro embryotoxicity tests. Altern Lab Anim 32: 209-244.
16. Gerami-Naini B, Dovzhenko OV, Durning M, Wegner FH, Thomson JA, Golos TG. 2004. Trophoblast differentiation in embryoid bodies derived from human embryonic stem cells. Endocrinology 145: 1517-1524.
17. Gilbert SF. 2003. Developmental biology. Sunderland, Massachusetts: Sinauer Associates, Inc. p 750.
18. Gill J. 2000. The effects of moderate alcohol consumption on female hormone levels and reproductive function. Alcohol Alcohol 35: 417-423.
19. Guibourdenche J, Fournier T, Malassine A, Evain-Brion D. 2009. Development and hormonal functions of the human placenta. Folia Histochem Cytobiol 47: 35-40.
20. Hendrickx AG. 1998. Teratogenicity of retinoids in rodents, primates and humans. J Toxicol Sci 4: 272.
21. Hofer T, Gerner I, Gundert-Remy U, Liebsch M, Schulte A, Spielmann H, Vogel R, Wettig K. 2004. Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation. Arch Toxicol 78: 549-564.
22. Hong L, Levy SM, Warren JJ, Dawson DV, Bergus GR, Wefel JS. 2005. Association of amoxicillin use during early childhood with developmental tooth enamel defects. Arch Pediatr Adolesc Med 159: 943-948.
23. Hubel V, Straube W, Loh M, Wodrig W, Weber A, Klima F. 1989. Human early pregnancy factor and early pregnancy associated protein before and after therapeutic abortion in comparison with beta-hCG, estradiol, progesterone and 17-hydroxyprogesterone. Exp Clin Endocrinol 94: 171-176.
24. Hurtt ME, Cappon GD, Browning A. 2003. Proposal for a tiered approach to developmental toxicity testing for veterinary pharmaceutical products for food-producing animals. Food Chem Toxicol 41: 611-619.
25. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 8: 711-715.
26. Krtolica A, Ilic D, Genbacev O, Miller RK. 2009. Human embryonic stem cells as a model for embryotoxicity screening. Regen Med 4: 449-459.
27. Kuegler PB, Zimmer B, Waldmann T, Baudis B, Ilmjärv S, Hescheler J, Gaughwin P, Brundin P, Mundy W, Bal-Price AK, Schrattenholz A, Krause KH, van Thriel C, Rao MS, Kadereit S, Leist M. 2010. Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing. ALTEX 27: 17-42.
28. Lee JE, Pintar J, Efstratiadis A. 1990. Pattern of the insulin-like growth factor II gene expression during early mouse embryogenesis. Development 110: 151-159.
29. Mamidi MK, Pal R, Bhonde R, Zakaria Z, Totey S. 2010. Application of multiplex PCR for characterization of human embryonic stem cells (hESCs) and its differentiated progenies. J Biomol Screen 15: 630-643.
30. Maynard S, Swistowska AM, Lee JW, Liu Y, Liu ST, Da Cruz AB, Rao M, de Souza-Pinto NC, Zeng X, Bohr VA. 2008. Human embryonic stem cells have enhanced repair of multiple forms of DNA damage. Stem Cells 26: 2266-2274.
31. McNeish J. 2004. Embryonic stem cells in drug discovery. Nat Rev 3: 70-80.
32. Mehta A, Konala VB, Khanna A, Majumdar AS. 2008. Assessment of drug induced developmental toxicity using human embryonic stem cells. Cell Biol Int 32: 1412-1424.
33. Miller RK, Peters PW, Schaefer CE. 2007. General commentary on drug therapy and drug risks in pregnancy. In: Schaefer CE, Peters PW, Miller RK, editors. Drugs during pregnancy and lactation, 2nd edition. New York, USA: Academic Press.
34. Nathanson S, Moreau E, Merlet-Benichou C, Gilbert T. 2000. In utero and in vitro exposure to beta-lactams impairs kidney development in the rat. J Am Soc Nephrol 11: 874-884.
35. Nau H. 1993. Embryotoxicity and teratogenicity of topical retinoic acid. Skin Pharmacol 11: 35-44.
36. Niwa H, Toyooka Y, Shimosato D, Strumpf D, Takahashi K, Yagi R, Rossant J. 2005. Interaction between Oct3/4 and CDX2 determines trophectoderm differentiation. Cell 123: 917-929.
37. Pal R, Totey S, Krishna M, Bhat VS, Totey SM. 2009. Distinct propensity of human embryonic stem cell during early stage of lineage specification controls their terminal differentiation into mature cell types. Exp Biol Med 234: 1230-1243.
38. Pal R, Totey S, Deb K. 2010. Application of human embryonic stem (hES) cells in drug discovery: A boon to pharmaceutical industries. Stem cell technologies: Basics and applications, 1st edition. McGraw-Hill. Ch 15, pp 293-308.
39. Paparella M, Kolossov BK, Fleischmann BK, Hescheler J, Bremer S. 2002. The use of quantitative image analysis in the assessment of in vitro embryotoxicity end point based on a novel embryonic stem cell clone with endoderm-related GFP expression. Toxicol In Vitro 16: 589-597.
40. Pellizzer C, Adler S, Corvi R, Hartung T, Bremer S. 2004. Monitoring of teratogenic effects in vitro by analysing a selected gene expression pattern. Toxicol In Vitro 3: 325-335.
41. Rohwedel J, Guan K, Hegert C, Wobus AM. 2001. Embryonic stem cells as an in vitro model for mutagenicity, cytotoxicity and embryotoxicity studies: Present state and future prospects. Toxicol In Vitro 6: 741-753.
42. Sartipy P, Bjorquist P, Strehl R, Hyllner J. 2007. The application of human embryonic stem cell technologies to drug discovery. Drug Discov Today 12: 688-699.
43. Scholz G, Pohl I, Genschow E, Klemm M, Spielmann H. 1999. Embryotoxicity screening using embryonic stem cells in vitro: Correlation to in vivo teratogenicity. Cells Tissues Organs 3-4: 203-211.
44. Seiler A, Viisan A, Buesen R, Genschow E, Spielmann H. 2004. Improvement of an in vitro stem cell assay for developmental toxicity: The use of molecular endpoints in the embryonic stem cell test. Reprod Toxicol 18: 231-240.
45. Shuey DL, Setzer RW, Lau C, Zucker RM, Elstein KH, Narotsky MG, Kavlock RJ, Rogers JM. 1995. Biological modeling of 5-fluorouracil developmental toxicity. Toxicology 1-2: 207-213.
46. Sivasubramaniyan K, Pal R, Totey S, Bhat VS, Totey S. 2010. Rho kinase inhibitor y27632 alters the balance between pluripotency and early differentiation events in human embryonic stem cells. Curr Stem Cell Res Ther 5: 2-12.
47. Spielmann H, Pohl I, Doering B, Liebsch M, Moldenhauer F. 1997. The embryonic stem cell test, an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embryonic stem cells. In Vitro Toxicol 119-127.
48. Wallace KL. 1997. Antibiotic-induced convulsions. Crit Care Clin 13: 741-762.
49. Yoon BS, Yoo SJ, Lee JE, You S, Lee HT, Yoon HS. 2006. Enhanced differentiation of human embryonic stem cells into cardiomyocytes by combining hanging drop culture and 5-azacytidine treatment. Differentiation 74: 149-159.
50. Young SL, Lessey BA. 2010. Progesterone function in human endometrium: Clinical perspectives. Semin Reprod Med 28: 5-16.
51. Zdravkovic T, Genbacev O, LaRocque N, McMaster M, Fisher S. 2008. Human embryonic stem cells as a model system for studying the effects of smoke exposure on the embryo. Reprod Toxicol 26: 86-93.